Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $7.55 USD
Change Today +0.10 / 1.34%
Volume 190.9K
CCXI On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 03/31/15 All times are local (Market data is delayed by at least 15 minutes).

chemocentryx inc (CCXI) Snapshot

Open
$7.41
Previous Close
$7.45
Day High
$7.68
Day Low
$7.30
52 Week High
01/29/15 - $9.20
52 Week Low
12/5/14 - $4.06
Market Cap
328.7M
Average Volume 10 Days
134.4K
EPS TTM
$-1.08
Shares Outstanding
43.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CHEMOCENTRYX INC (CCXI)

Related News

No related news articles were found.

chemocentryx inc (CCXI) Related Businessweek News

No Related Businessweek News Found

chemocentryx inc (CCXI) Details

ChemoCentryx, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders, and cancer in the United States. Its drug candidates under clinical stage include Vercirnon, which is in Phase III clinical trial for the treatment of patients with moderate-to-severe Crohn’s disease; CCX140 that is in Phase II clinical trial for the treatment of patients with diabetic nephropathy, a form of kidney disease; and CCX354 that completed a Phase II proof-of-concept clinical trial for the treatment of rheumatoid arthritis. The company’s drug candidates also comprise CCX168, which is in a Phase II clinical trial for the treatment of anti-neutrophil cytoplasmic antibody associated renal vasculitis; CCX872 that is under Phase I clinical development targeting CCR2 for expanded indications of renal disease; and CCX507, a de novo wholly-owned CCR9 inhibitor, which is in Phase I clinical trials for inflammatory bowel disease and related disorders. Its preclinical stage programs comprise CCX650, an orally active drug for the treatment of glioblastoma multiforme; CCR4 inhibitor for atopic dermatitis; CCX6239, an orally administered CCR4 antagonist with potential utility in the treatment of atopic dermatitis; CCR6 inhibitor for autoimmune diseases; and CXCR6 inhibitor for liver diseases. The company was founded in 1997 and is headquartered in Mountain View, California.

58 Employees
Last Reported Date: 03/13/15
Founded in 1997

chemocentryx inc (CCXI) Top Compensated Officers

Founder, Chairman, Chief Executive Officer an...
Total Annual Compensation: $510.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $372.2K
Chief Medical Officer
Total Annual Compensation: $369.4K
Compensation as of Fiscal Year 2013.

chemocentryx inc (CCXI) Key Developments

ChemoCentryx, Inc. Reports Consolidated Financial Results for the Fourth Quarter and Year Ended December 31, 2014

ChemoCentryx, Inc. reported consolidated financial results for the fourth quarter and year ended December 31, 2014. For the quarter the company reported, no revenue compared to $0.7 million in the same period in 2013. The decrease in revenues from 2013 to 2014 was primarily due to funding of clinical support from former partner, GlaxoSmithKline (GSK), for CCX168, the Company's C5aR inhibitor, in 2013. Net loss was $12.2 million for the fourth quarter of 2014 compared to $9.5 million in the same period in 2013. Loss from operations was $12.290 million compared to $9.671 million a year ago. Basic and diluted net loss per share was $0.28 compared to $0.22 a year ago. For the year the company reported, no revenue compared to $6.1 million in the same period in 2013. Loss from operations was $47.399 million compared to $39.115 million a year ago. Net loss was $46.929 million compared to $38.673 million a year ago. Basic and diluted net loss per share was $1.08 compared to $0.95 a year ago.

ChemoCentryx, Inc. to Report Q4, 2014 Results on Mar 12, 2015

ChemoCentryx, Inc. announced that they will report Q4, 2014 results at 5:00 PM, US Eastern Standard Time on Mar 12, 2015

ChemoCentryx, Inc., Q4 2014 Earnings Call, Mar 12, 2015

ChemoCentryx, Inc., Q4 2014 Earnings Call, Mar 12, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CCXI:US $7.55 USD +0.10

CCXI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CCXI.
View Industry Companies
 

Industry Analysis

CCXI

Industry Average

Valuation CCXI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 2.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CHEMOCENTRYX INC, please visit www.chemocentryx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.